Shammas Masood A, Qazi Aamer, Batchu Ramesh B, Bertheau Robert C, Wong Jason Y Y, Rao Manjula Y, Prasad Madhu, Chanda Diptiman, Ponnazhagan Selvarangan, Anderson Kenneth C, Steffes Christopher P, Munshi Nikhil C, De Vivo Immaculata, Beer David G, Gryaznov Sergei, Weaver Donald W, Goyal Raj K
Department of Surgery, Wayne State University and Karmanos Cancer Institute, Detroit, Michigan 48201, USA.
Clin Cancer Res. 2008 Aug 1;14(15):4971-80. doi: 10.1158/1078-0432.CCR-08-0473.
The aims of this study were to investigate telomere function in normal and Barrett's esophageal adenocarcinoma (BEAC) cells purified by laser capture microdissection and to evaluate the effect of telomerase inhibition in cancer cells in vitro and in vivo.
Epithelial cells were purified from surgically resected esophagi. Telomerase activity was measured by modified telomeric repeat amplification protocol and telomere length was determined by real-time PCR assay. To evaluate the effect of telomerase inhibition, adenocarcinoma cell lines were continuously treated with a specific telomerase inhibitor (GRN163L) and live cell number was determined weekly. Apoptosis was evaluated by Annexin labeling and senescence by beta-galactosidase staining. For in vivo studies, severe combined immunodeficient mice were s.c. inoculated with adenocarcinoma cells and following appearance of palpable tumors, injected i.p. with saline or GRN163L.
Telomerase activity was significantly elevated whereas telomeres were shorter in BEAC cells relative to normal esophageal epithelial cells. The treatment of adenocarcinoma cells with telomerase inhibitor, GRN163L, led to loss of telomerase activity, reduction in telomere length, and growth arrest through induction of both the senescence and apoptosis. GRN163L-induced cell death could also be expedited by addition of the chemotherapeutic agents doxorubicin and ritonavir. Finally, the treatment with GRN163L led to a significant reduction in tumor volume in a subcutaneous tumor model.
We show that telomerase activity is significantly elevated whereas telomeres are shorter in BEAC and suppression of telomerase inhibits proliferation of adenocarcinoma cells both in vitro and in vivo.
本研究旨在调查通过激光捕获显微切割纯化的正常和巴雷特食管腺癌(BEAC)细胞中的端粒功能,并评估端粒酶抑制在体外和体内癌细胞中的作用。
从手术切除的食管中纯化上皮细胞。通过改良的端粒重复序列扩增协议测量端粒酶活性,并通过实时PCR测定法确定端粒长度。为了评估端粒酶抑制的作用,用特异性端粒酶抑制剂(GRN163L)连续处理腺癌细胞系,并每周测定活细胞数量。通过膜联蛋白标记评估细胞凋亡,通过β-半乳糖苷酶染色评估衰老。对于体内研究,将严重联合免疫缺陷小鼠皮下接种腺癌细胞,在出现可触及的肿瘤后,腹腔注射生理盐水或GRN163L。
与正常食管上皮细胞相比,BEAC细胞中端粒酶活性显著升高,而端粒较短。用端粒酶抑制剂GRN163L处理腺癌细胞导致端粒酶活性丧失、端粒长度缩短,并通过诱导衰老和凋亡导致生长停滞。添加化疗药物阿霉素和利托那韦也可以加速GRN163L诱导的细胞死亡。最后,在皮下肿瘤模型中,用GRN163L治疗导致肿瘤体积显著减小。
我们表明,BEAC中端粒酶活性显著升高,而端粒较短,端粒酶的抑制在体外和体内均抑制腺癌细胞的增殖。